anti-endomysium and anti-gliadin antibodies were measured using ELISA.
ACTH levels in her 33-year-old daughter were above the normal range, with a cortisol level of 1.58 mcg/dL. She also exhibited subclinical hyperthyroidism and anti thyroperoxidase antibodies, anti-TG antibodies, and she was positive for Thyroid-stimulating immunoglobulin (TSI), anti-endomysial and anti-gliadin antibodies. The two boys, 37 and 33 years of age, were euthyroid and positive for antithyroid antibodies. The boys exhibited low cortisol levels of 3.4 and 3.6 mcg/dL, respectively. They were tested to confirm adrenal insufficiency using low-dose cosyntropin (1 mg) and exhibited positive results. Immediate substitution was initiated.
We investigated the genes of the human leukocyte antigen (HLA) class I system (HLA-A, HLA-B, HLA-C) and class II (HLA-DR, HLA-DQ) to examine the genetic basis of autoimmunity in this family, and Figure 1 shows the results. The genealogy revealed that all of the affected individuals were positive for the HLA DRB1*04, HLA DRB1*16, and HLA DRB1*14 alleles, which are associated with several forms of autoimmunity in the Mexican population. Some individuals were heterozygous HLA DRB1*04/DRB1*16 or homozygous for HLA DRB1*04, which suggests that susceptibility to autoimmunity was inherited via parental and maternal ancestries (Table 2) . The clinically manifested syndrome is considered only a fraction of the autoimmune background because latent forms are even more frequent. The combination of autoimmune adrenal insufficiency and autoimmune thyroid disease is known as Schmidt syndrome, 2 which was the case in our patient. Notably, the prolactin elevation that the patient experienced at the beginning of her disease may be due to hypothyroidism, which causes hyperplasia and stimulation of the lactotroph cells in the anterior pituitary gland. This presentation explains the disappearance of hyperprolactinemia following treatment with thyroid hormone. Therefore, the abnormality seen in her initial tomography was a pituitary incidentaloma. APS 2 primarily appears between 20 and 60 years of age, and subsequent generations are commonly affected. More than 20 years may elapse between the onset of one endocrinopathy and the diagnosis of the next episode, which means that 40%-50% of the subjects with Addison's disease will develop an autoimmune endocrinopathy over time. 3 Carpenter reviewed 142 cases of Schmidt's syndrome, and Hashimoto's thyroiditis was the primary thyroid autoimmune disease. The remaining cases exhibited Graves' disease. The complete triad of Addison's disease, autoimmune thyroid disease, and DM1 is called Carpenter's syndrome. 3 Patients will often not exhibit polyglandular failure at the onset of the clinical symptoms of autoimmune disease. Notably, the tests that should be used and the frequency with which they should be performed in anticipation of the occurrence of autoimmune diseases remain controversial. 4 APS 2 is primarily associated with HLA class II alleles, particularly DQ2 and DQ8, which is similar to many autoimmune diseases. APS 2 is strongly associated with HLA DR3/DQ2 (DQ2: DQA1*0501, DQB1*0201) and DR4/DQ8 (DQ8:DQA1*0301, DQB1*0302) and DRB1*0404. Other diseases associated with HLA-B8 and DR3 include IgA deficiency, juvenile dermatomyositis, dermatitis herpetiformis, alopecia, scleroderma, autoimmune thrombocytopenic purpura, hypophysitis, metaphyseal osteopenia, serositis, and premature ovarian failure. 5, 6 Botta et al 7 examined HLA in the members of two families with APS 2 and APS 3. The polymorphism DRB1*0301-DQB1*0201 was found in at least two of the members of each of these families, who were asymptomatic. Therefore, the identification of individuals carrying these polymorphisms may allow early intervention and reduce the chronic morbidity of these diseases, which are often subclinical or latent.
7
Mallea Gil et al 8 reported the case of a man who was diagnosed with APS 2. He arrived at the emergency room in a state of shock, and they identified HLA DQB1*0302. This haplotype was described in previous cases, but the HLA DRB1 * 08 that was also found in this patient was not described in any other autoimmune disorder. These cases likely explain the variability of the affected locus. APS 2 is a polygenic disorder that produces polymorphisms that may increase the risk or protect against autoimmune diseases. For example, molecules of the major histocompatibility complex, such as DR and DQ, are associated with the development of the autoantibodies against hydroxylase that are associated with the clinical progression of adrenal failure, and HLA-B15 is associated with the protection of the progression of adrenal insufficiency in individuals with positive 21-hydroxylase autoantibodies. Salinas-Santander et al 10 evaluated 198 Mexican patients with vitiligo and found an association of it with the presence of autoimmune thyroid disease in 23% of these patients. To our knowledge, there is no report of an HLA association in a Mexican family with APS 2 in the literature. Therefore, this case may be the first presentation of the clinical manifestations, the biochemical determination of antibodies, and the HLA association. The treatment of APS generally consists of the adequate substitution of the compromised axes. This substitution is vitally important because it allows for the early detection of adrenal failure and avoids catastrophic outcomes. 11 
| CONCLUSIONS
A polyglandular syndrome diagnosis should be suspected in patients with an autoimmune background. The presence of an endocrine disease suggests that other endocrine axes may be affected subsequently.
Antibody positivity and symptoms may manifest over time, and the identification of HLA polymorphisms, if available, could be useful in select patients with autoimmunity.
Examination of all of the patient's children identified adrenal and thyroid autoimmunity to initiate timely treatment.
